IFNG and non-small cell lung carcinoma: The findings of a recent phase Ib trial showed that the administration of nivolumab in combination with an IL15 superagonist led to expansion of NK cells and CD8+ T cells as well as raised serum concentration of IFNG in patients with NSCLC.49